| Arthritis is defined as an inflammatory syndrome that occurs within joints,contributing to various clinical symptoms,such as pain,swelling,motion ability reduction,and even disability,which reduces the living standards of patients.With the aging of the population and the increase in obesity in recent years,the arthritis population increasingly ascend.However,current therapies could relieve the arthritis symptoms slightly and have limitations in preventing arthritis progression.Thus,providing an efficient method to deal with this disease and improve these severe symptoms is urgent.Herein,aiming to overcome TA defects in clinical usage and meet the increasing demand for clinical transformation,we designed and optimized a TA-loaded tunable in situ forming implants transformed from a polymer solution.This injectable polymer solution adopts poly(lactic-co-glycolic acid)(PLGA)as extended-release material,instantaneously solidified into implants via a solvent exchange in the aqueous environment,then TA was trapped in a 3D net-like structure.With robust retention in situ and high drug compatibility,the implants released TA for several weeks or months through diffusion and erosion.Moreover,the drug release period is precisely tunable by adding different proportions of low water-miscible plasticizers.The plasticizersimproved implants with a tough texture greatly ameliorate TA efficiency and safety in vivo.Furthermore,the TA-loaded tunable implants significantly improve the swelling,pain,and motor discoordination in arthritic mice and suppress the arthritis progression to some extent.The plasticizers-improved ISFI has outstanding advantages in the sustained release of drugs,injectability,and retention in situ,which is expected to be a promising extended-release system to improve the symptoms and inhibit the progression of arthritis for clinical transformation.This study provides a promising platform for managing inflammatory disorders of arthritis individuals. |
PDF Full Text Request